COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01087671
Recruitment Status : Completed
First Posted : March 16, 2010
Last Update Posted : May 31, 2013
Information provided by (Responsible Party):
Santen Oy

Brief Summary:
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Condition or disease Intervention/treatment Phase
Ocular Hypertension Open-Angle Glaucoma Drug: tafluprost Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 185 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ocular Signs and Symptoms in Patients With Ocular Hypertension or Open-angle Glaucoma Switched From Preserved Latanoprost 0.005% Eye Drops to Preservative Free Tafluprost Eye Drops
Study Start Date : April 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
Drug Information available for: Tafluprost

Arm Intervention/treatment
Open-lable study with one arm Drug: tafluprost
prostaglandin analogue

Primary Outcome Measures :
  1. Assessment of changes in ocular symptoms and signs [ Time Frame: From Screening (Visit 1) to12 weeks. ]

    Ocular symptoms include: irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation.

    Following signs will be evaluated: tear break-up time, corneal and conjunctival fluorescein staining, blepharitis, conjunctival redness and tear secretion (schirmer test).

Secondary Outcome Measures :
  1. Secondary outcome measures include the assessment of safety and quality of life parameters. [ Time Frame: From Screening (visit 1) to 12 weeks ]
    Safety parameters include: best-corrected visual acuity, biomicroscopy, ophthalmoscopy, visual field test, drop discomfort upon instillation, intra ocular pressure, quality of life and adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication.
  • Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01087671

Sponsors and Collaborators
Santen Oy
Layout table for investigator information
Principal Investigator: Evgeniy Egorov, Professor State Educational Establishment of Higher Professional Education "Russian State Medical University of Federal Service on Surveillance in Healthcare and Social Development of Russian Federation"
Layout table for additonal information
Responsible Party: Santen Oy Identifier: NCT01087671    
Other Study ID Numbers: 77553
First Posted: March 16, 2010    Key Record Dates
Last Update Posted: May 31, 2013
Last Verified: November 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases